EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Stem Cell‐Based Delivery of Immunomodulators for Overcoming Glioblastoma Immune Evasion

Mustafa T-Ardah, H Malathi, Laxmidhar Maharana iD, Archana Dhyani, Shaker Al-Hasnaawei, Ashish Singh-Chauhan, Vimal Arora, Jatin Sharma, Manoj Kumar-Mishra

Immunology · 2026

DOI: 10.1111/imm.70102 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology, 2026. Verfasst von Mustafa T-Ardah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Neoplastic Stem Cells, Tumor Escape. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 99 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most aggressive primary brain tumour in adults, characterised by rapid progression, extensive heterogeneity, and poor outcomes despite surgery, radiotherapy, and temozolomide (TMZ). A subpopulation of glioblastoma stem cells (GSCs) with self‐renewal and multi‐lineage differentiation capabilities drives tumour initiation, progression, recurrence, and therapeutic resistance. GSCs evade conventional treatments via enhanced DNA repair, multidrug efflux, activation of survival pathways, epigenetic reprogramming, and entry into quiescent states. Moreover, these cells utilise key immune escape mechanisms, such as downregulation of major histocompatibility complex molecules and the secretion of immunosuppressive factors, to escape detection and destruction by the immune system. Evidence suggests that transformed neural stem cells are a likely source of GSCs, with key survival networks including EGFR, FGFR, HGFR, and PI3K/AKT/mTOR signalling. Their phenotypic plasticity and adaptability to the tumour microenvironment further complicate eradication. Stem cell‐based strategies utilising NSCs, MSCs, haematopoietic stem/progenitor cells, or induced pluripotent stem cells can effectively deliver immunomodulators to counteract these immune evasion mechanisms, exploiting tumour tropic migration to deliver therapeutic payloads into hypoxic and infiltrative niches. Approaches such as suicide gene therapy, oncolytic virus delivery, and CXCL12—CXCR4 axis modulation aim to target both proliferative and dormant GSCs. Preclinical studies demonstrate promising efficacy, yet challenges remain, including safety concerns, variability in outcomes, and the limited translational relevance of current models. This review provides a concise overview of GSC biology, resistance mechanisms, and emerging stem cell‐based interventions, highlighting opportunities and obstacles in developing effective therapies for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsNeoplastic Stem CellsTumor EscapeStem Cell TransplantationImmunologic FactorsHumansAnimalsTumor MicroenvironmentSignal Transduction

Stichwörter der Autor:innen

glioblastomaglioblastoma stem cellsstem cell therapytargeted therapytherapy resistance

Substanzen

Immunologic Factors

Autor:innen und Institutionen

  • Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
  • Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed To Be University), Bangalore, Karnataka, India.
  • Department of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed To Be University), Bhubaneswar, Odisha, India.
  • Department of Pharmacy, Graphic Era Hill University, Dehradun, India.
  • Centre for Promotion of Research, Graphic Era Deemed To Be University, Dehradun, Uttarakhand, India.
  • College of Pharmacy, The Islamic University, Najaf, Iraq.

ORCID-Profile: Laxmidhar Maharana

Zitieren

APA

T-Ardah, M., Malathi, H., Maharana, L., Dhyani, A., Al-Hasnaawei, S., Singh-Chauhan, A., Arora, V., Sharma, J., & Kumar-Mishra, M. (2026). Stem Cell‐Based Delivery of Immunomodulators for Overcoming Glioblastoma Immune Evasion. Immunology. https://doi.org/10.1111/imm.70102

Vancouver

T-Ardah M, Malathi H, Maharana L, Dhyani A, Al-Hasnaawei S, Singh-Chauhan A, et al. Stem Cell‐Based Delivery of Immunomodulators for Overcoming Glioblastoma Immune Evasion. Immunology. 2026. doi:10.1111/imm.70102

BibTeX
@article{TArdah2026,
  author = {T-Ardah, Mustafa and Malathi, H and Maharana, Laxmidhar and Dhyani, Archana and Al-Hasnaawei, Shaker and Singh-Chauhan, Ashish and Arora, Vimal and Sharma, Jatin and Kumar-Mishra, Manoj},
  title = {Stem Cell‐Based Delivery of Immunomodulators for Overcoming Glioblastoma Immune Evasion},
  journal = {Immunology},
  year = {2026},
  doi = {10.1111/imm.70102}
}
Kostenlos starten →